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ABSTRACT
Objectives To investigate whether preoperative 
echocardiographic evaluation of ventricular function, 
especially right ventricular systolic and diastolic 
parameters including speckle-tracking analysis, could aid 
in the prediction of 30-day mortality after transcatheter 
aortic valve implantation (TAVI) in patients with aortic 
stenosis.
Methods This is a prospective observational cohort study 
including 227 patients accepted for TAVI at the University 
Hospital of North Norway and Oslo University Hospital from 
February 2010 through June 2013. All patients underwent 
preoperative transthoracic echocardiography with 
retrospective speckle-tracking analysis. Primary endpoint 
was all-cause 30-day mortality.
Results All-cause 30-day mortality was 8.7 % (n = 19). 
Independent predictors of 30-day mortality were systolic 
pulmonary arterial pressure (SPAP) > 60 mm Hg (HR: 
7.7, 95% CI: 1.90 to 31.3), heart failure (HR: 2.9, 95% CI: 
1.1 to 7.78), transapical access (HR: 3.8, 95% CI: 1.3 
to 11.2), peripheral artery disease (HR: 6.0, 95% CI: 2.0 
to 18.0) and body mass index (HR: 0.73, 95% CI: 0.61 
to 0.87). C-statistic for the model generated was 0.91 
(95% CI: 0.85 to 0.98). Besides elevated SPAP, no other 
echocardiographic measurements were found to be an 
independent predictor of early mortality.
Conclusion Except for elevated systolic pulmonary 
artery pressure, our data suggests that clinical rather than 
echocardiographic parameters are useful predictors of 
30-day mortality after TAVI.
IntROduCtIOn
Transcatheter aortic valve implantation 
(TAVI) has become a treatment option for 
a growing number of patients with aortic 
stenosis (AS) with intermediate to high 
risk for surgical aortic valve replacement 
(SAVR).1 However, there are still uncertain-
ties about risk factors of early mortality for 
these patients. Identifying predictors of early 
mortality is important in order to improve 
patient selection and to give patients a better 
basis for informed consent. TAVI is now 
performed in patients with intermediate 
risk for SAVR2 and there are ongoing studies 
even in low-risk patients (NOTION-2/
NCT02825134, PARTNER 3/NCT02675114, 
Medtronic Evolut Transcatheter Aortic 
Valve Replacement in Low Risk Patients/
NCT02701283). These patients are still 
candidates for open surgery where the risk 
factors are better identified and incorpo-
rated into validated risk algorithms. Despite 
the development of novel TAVI-specific risk 
algorithms,3–6 risk factors specific for TAVI 
are currently not fully understood. Both 
established surgical and novel TAVI-specific 
risk algorithms are comprised primarily of 
clinical parameters with the exception of 
systolic pulmonary arterial pressure (SPAP) 
and ejection fraction (EF). While the eval-
uation of left ventricular (LV) function on 
the outcome after TAVI has been extensively 
studied,7 8 the knowledge of the impact of 
right ventricular (RV) function on periproce-
dural outcome is still limited. RV dysfunc-
tion is linked to adverse outcome in several 
cardiovascular conditions including AS and 
heart failure.9 10 The aim of our study was to 
investigate whether preoperative echocardi-
ographic evaluation of ventricular function, 
especially RV systolic and diastolic parame-
ters including speckle-tracking analysis, in 
Key questions
What is already known about this subject?
 ► Prediction of early mortality after transcatheter aor-
tic valve implantation (TAVI) is still imprecise.
What does this study add?
 ► Despite a thorough preoperative echocardiographic 
evaluation of left and right ventricular function, in-
cluding speckle-tracking analysis, our data suggest 
that clinical parameters are more useful than echo-
cardiographic measurements as predictors of early 
mortality after TAVI.
How might this impact clinical practice?
 ► When evaluating patients for TAVI, our data suggest 
that clinical rather than echocardiographic param-
eters are more useful in predicting early mortality. 
Whether this remains the case in today’s TAVI popu-
lation, which is younger and with fewer comorbidi-
ties, has yet to be determined.
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addition to clinical parameters could aid in the predic-
tion of unfavourable early outcome after TAVI.
MetHOds
study population
From February 2010 through June 2013, 227 patients 
from the University Hospital of North Norway Tromsø and 
Oslo University Hospital Rikshospitalet with severe symp-
tomatic AS accepted for TAVI were included in the study. 
A multidisciplinary heart team determined the patient 
suitability for TAVI considering cognitive function and 
comorbid status of the patient as well as technical feasi-
bility. Patients with inability to give informed consent, life 
expectancy less than 12 months and low motivation for 
treatment were not offered TAVI. Primary endpoint was 
all-cause 30-day mortality classified according to the Valve 
Academic Research Consortium (VARC)-2 criteria.11 The 
study was approved by the Regional Ethical Commit-
tees for Medical Research Ethics, North and South East 
Norway. All patients gave written informed consent.
Patient characteristics
Patient demographics, clinical characteristics, periproce-
dural mortality and complications were obtained from 
the patients’ electronic records. Chronic obstructive 
pulmonary disease (COPD) was classified according to 
the global initiative for chronic obstructive lunge disease 
(GOLD) classification. Patients with COPD of unknown 
grade were classified as having grade 1. Previous cere-
brovascular events comprised both previous strokes and 
transient ischaemic attacks. Chronic and paroxysmal 
atrial fibrillation/flutter was grouped as one variable. 
Heart failure was defined as physician-documented clin-
ical signs of heart failure in the form of unusual dyspnoea 
on light exertion, orthopnoea, fluid retention, rales on 
auscultation or pulmonary oedema on chest X-ray less 
than 2 weeks prior to TAVI. Peripheral artery disease 
(PAD) was defined as claudication, previous amputation 
due to vascular insufficiency, previous reconstructive 
surgery or percutaneous intervention, abdominal aortic 
aneurism and/or >50% stenosis in a peripheral artery 
diagnosed by CT or angiographic imaging.
echocardiography
All patients underwent preoperative transthoracic echo-
cardiographic evaluation with either an iE33 (S5-1 probe, 
Philips Medical systems, Andover, MA) or a Vivid E9 (GE 
Vingmed, Horten, Norway) scanner using a 2.5–3.5 MHz 
transducer in the left lateral decubital position. Conven-
tional two-dimensional grey-scale images were obtained 
in the parasternal long-axis and short-axis view, as well as 
the apical four-chamber, two-chamber and three-chamber 
views. Left ventricular EF (LVEF) was derived from the 
Simpson’s biplane method. The same two views served 
to calculate left atrial volumes at end-systole. LV longi-
tudinal function was assessed by mitral annular plane 
systolic excursion in the septal and lateral mitral ring in 
the apical four-chamber view. Intraventricular septum 
thickness in diastole was measured in M-mode images 
in the parasternal long-axis view. Diastolic LV function 
was assessed by E/A ratio, E/e′ ratio and E deceleration 
time. The degree of AS was derived from the mean and 
peak gradient of the Doppler flow across the aortic valve, 
as well as the aortic valve area derived by the continuity 
equation. LV stroke volume, cardiac output and cardiac 
index were derived from the LV outflow tract (LVOT) 
diameter and LVOT velocity time integral. The degree 
of aortic regurgitation was estimated by the size of the 
regurgitation area by colour Doppler, pressure half-time 
and diastolic velocities in descending aorta by Doppler-
flow signal. The degree of mitral regurgitation (MR) was 
based on measurement and visual assessment of colour 
Doppler images, vena contracta and proximal isovelocity 
surface area.
RV geometry and function were evaluated in an 
adjusted four-chamber view at the largest transversal 
diameter of the RV. Systolic RV function was assessed by 
tricuspid annular peak systolic excursion (TAPSE) and 
tissue velocity imaging derived tricuspid annular systolic 
velocity in the basal RV free wall. RV areas were measured 
in end-diastole and end-systole and used for calculating 
fractional area change. RV longitudinal diameter in dias-
tole was measured as the distance from the RV apex to 
the middle of the RV annulus. RV mediolateral diam-
eter in diastole was measured from the intraventricular 
septum to the RV free wall at the widest part of the RV 
cavity. SPAP was derived from continuous wave Doppler 
measurements of tricuspid regurgitation (TR) and respi-
ratory variation of the diameter of the inferior vena cava. 
When TR gradient was not recorded, SPAP was consid-
ered being <30 mm Hg if TR was described by visual 
assessment as trivial or mild, and 30–60 mm Hg when TR 
was described as moderate.
strain analyses
Strain analyses were performed using speckle-tracking 
software VVI7 (Siemens, Mountain View, CA, USA). 
Longitudinal LV strain was obtained by analyses of the 
LV in the apical four-chamber, two-chamber and three-
chamber views. Longitudinal RV strain was obtained 
from an apical four-chamber view including segments 
of the lateral wall only (figure 1). The time point of the 
aortic valve closure was measured in continuous Doppler 
registrations of the aortic flow. Global strain peak longi-
tudinal strain values were extracted from strain curves by 
defining the systolic time interval between R-wave and 
the time point of aortic valve closure. Strain curves with 
artefacts due to reverberation, air artefact or insufficient 
tracking were discarded based on subjective visual assess-
ment. In patients with atrial arrhythmia, strain from three 
cycles, if available, was obtained and averaged.
tAVI procedure
All TAVI procedures were performed under general 
anaesthesia with transfemoral (TF), transaortic (TAo) 
or transapical (TA) access using either first-generation 
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Figure 1 Example of how the RV strain curves are 
generated from a two-dimensional four-chamber view. RV, 
right ventricular.
self-expanding Medtronic CoreValve (Medtronic, Minne-
apolis, MN, USA) or either first- or second-generation 
Edwards SAPIEN-SAPIEN XT balloon-expandable valve 
(Edwards Lifesciences, Irvine, CA, USA). Valve size was 
determined from the aortic annular diameter measured 
by CT scan reconstruction and/or transesophageal echo-
cardiography. TF access was the preferred modality. TA 
access was used in the presence of highly calcified and 
tortious pelvic vessels given acceptable LV and respira-
tory function. In the presence of inaccessible peripheral 
vessels and reduced LVEF or COPD, TAo access was used.
statistical analysis
The power of the study was calculated using the power 
calculation package in STATA V.12. We estimated a 
minimum detectable HR of 1.25 for mortality for a 
1-unit change for each echocardiographic variable with 
a power of 80% with a 5% probability of a false-negative 
result. Data are presented as number (%) or mean±SD 
as appropriate. Variables between groups were compared 
using Pearson χ2 or independent t-test for percentages 
and continuous variables, respectively. Univariable Cox 
regression analysis was performed for all-cause 30-day 
mortality. Variables with p<0.15 and deemed clinically 
relevant were selected and tested for interaction and 
co-linearity prior to forward and backward multivariable 
Cox regression analysis. When the interaction terms in 
the backwards analysis were non-significant, the forward 
model was used. No imputation for missing data was 
performed and multivariable analyses performed on 
all available patients for each analysis. The final model 
was based on 213 patients. P<0.05 in multivariable anal-
ysis was considered significant. C-statistic for predicted 
30-day mortality in our cohort was obtained from receiver 
operating characteristic (ROC) analyses of the predicted 
probabilities generated from binary logistic regression. 
All statistical analysis was done using SPSS V.24 (SPSS, 
Chicago, IL, USA).
Reproducibility
To determine the interobserver and intraobserver vari-
ability of longitudinal strain measurements, recordings 
from 30 patients were selected at random and another 
experienced observer repeated the analysis. The same 
data were reanalysed by the main observer after several 
months. Intraclass correlation coefficient was used to test 
interobserver and intra-observer variability.
Results
The patients’ demographics, clinical characteristics and 
periprocedural results are listed in table 1 and echocar-
diographic parameters in table 2. Nine patients were 
excluded from final analysis including three patients 
who did not undergo TAVI, five cases where preopera-
tive echocardiographic images were not accessible and 
one patient with aortic insufficiency and not stenosis. 
The remaining 218 patients were included in the final 
analysis. All-cause mortality at 30 days was 8.7% (n=19). 
Six (32%) of these patients died peroperatively. Postop-
eratively, 12 (63%) died of cardiovascular causes where 
three (16%) were due to myocardial infarction, five 
(26%) secondary to cerebrovascular event and one (5%) 
from either bleeding, worsening heart failure, procedure 
related or death of unknown cause. One (5%) died of 
non-cardiovascular cause due to subarachnoid haemor-
rhage secondary to trauma. These patients had signif-
icantly lower body mass index (BMI), higher periph-
eral vascular disease burden, more TA procedures and 
a higher percentage of patients with SPAP >60 mm Hg. 
The difference in the presence of moderate to severe 
MR and heart failure was borderline significant between 
the groups. There was no interaction between variables 
in our data consequently a forward multivariable regres-
sion analysis was performed. All clinically significant vari-
ables with p<0.15 in univariable analysis and the result 
of multivariable analysis are shown in table 3. All varia-
bles included in the final model were highly significant 
in univariable analysis and maintained significance after 
multivariable analysis. Figure 2 displays the Kaplan-Meier 
curves for each independent predictor of all-cause 30-day 
mortality.
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Table 1 Baseline demographics, clinical characteristics 







Age, years 82±7 80±8 0.330
Female 89(45) 9 (47) 0.825
Body surface area, m2 1.8±0.2 1.7±0.1 0.005
Body mass index, kg/m2 26±5 22±3 0.001
STS score 5.9±3.9 8.3±4.4 0.012
Euroscore 2 9.4±7.2 11.3±8.8 0.300
NYHA class 0.527
  II 29(15) 2 (11)
  III 120(60) 10(53)
  IV 50(25) 7 (37)
Heart failure 84(42) 12(63) 0.079
Hypertension 133(67) 15(79) 0.280
Atrial dysrhythmia 89(45) 11(58) 0.271
Previous myocardial 
infarction
76(38) 6 (32) 0.570
Previous PCI 78(39) 9 (47) 0.487
Previous cardiac surgery 93(47) 5 (26) 0.087
LBBB 18(9) 2 (11) 0.831
Peripheral artery disease 66(33) 14(74) <0.000
Porcelain aorta 21(11) 5 (26) 0.043
Cerebrovascular disease 52(26) 6 (32) 0.608
Previous cerebrovascular 
event
46(23) 6 (32) 0.408
Immunocompromised 24(12) 4 (21) 0.263
Diabetes 59(30) 3 (1.5) 0.201
COPD 70(35) 8 (42) 0.547
eGFR, ml/min/1.73 m2 54±20 50±24 0.055
Previous radiation therapy 8 (4) 1 (5) 0.795
Access 0.001
  Transfemoral 117(59) 5 (26)
  Transaortic 27(14) 1 (5)
  Transapical 55(28) 13(68)
Valve type 0.206
  Edwards Sapien 153(77) 17(89)
  CoreValve 46(23) 2 (11)
Periprocedural results 
  Intraoperative mortality − 6 (2.8)
  Myocardial infarction 3 (1.5) 3 (16) <0.000
  Cerebrovascular event 6 (3) 7 (37) <0.000
  Major or life-threatening 
bleeding
5 (2.5) 5 (26) <0.000







  Permanent PM 
postoperatively
17 (8.5) 0 (0) −
Values are mean±SD or n (%)
COPD, chronic obstructive pulmonary disease; LBBB, left 
bundle branch block;NYHA, New York Heart Association; PCI, 
percutaneous coronary intervention; PM, pacemaker; PVL, 
paravalvular leakage; STS, society of thoracic surgeons; eGFR, 
estimated glomerular filtration rate; eGFR, estimated glomerular 
filtration rate.
Table 1 Continued
SPAP >60 mm Hg was the only independent echocar-
diographic predictor of early mortality and was present 
in 21 (9.6%) of the patients. In all, 14 (67%) of these had 
clinical signs of heart failure prior to surgery, 11 (52%) 
had COPD and 6 (29%) had both. Out of the 21 patients 
with SPAP >60 mm Hg, five (24%) died within 30 days 
after treatment, with three having concomitant clinical 
signs of heart failure, two had COPD and one had both. 
Heart failure was present in 12 (63%) patients with early 
mortality compared with 96 (44%) in the whole cohort. 
Neither New York Heart Association (NYHA) IV nor 
NYHA III and IV combined were identified as risk factors 
by univariable analysis. TA access with concomitant PAD 
was present in 12 (63%) patients who died within 30 days 
compared with 22 (11%) of the survivors. All of these 
patients died of cardiovascular causes. BMI was analysed 
as a continuous variable and was still statistically signifi-
cant as a predictor of early mortality even when patients 
with BMI <20 kg/m2 (n=17) were excluded from analyses 
(HR: 0.79, 95% CI: 0.649 to 0.97, p=0.025). C-statistic for 
the model generated from multivariable regression anal-
ysis in our cohort was 0.91 (95% CI: 0.85 to 0.98).
Reproducibility
Intraclass correlation coefficient for longitudinal strain 
measurement was 0.799 (95% CI 0.695 to 0.868) and 
0.924 (95% CI 0.885 to 0.950) for interobserver and 
intraobserver variability, respectively.
dIsCussIOn
All-cause 30-day mortality rate was 8.7% which is similar 
to registry data from the same period.12 All but one 
patient died of cardiovascular causes as defined by the 
VARC-2 criteria.11 In our study, we identified SPAP >60 
mm Hg, heart failure, TA access, PAD and BMI as inde-
pendent predictors of 30-day mortality after TAVI and the 
model showed high accuracy in ROC analysis correctly 
allocating 91% as cases or controls.
Despite a thorough preoperative echocardiographic 
evaluation, especially of RV systolic and diastolic func-
tional parameters, we did not identify any echocardio-
graphic marker for early mortality except for SPAP >60 
mm Hg.
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Table 2 Preoperative echocardiographic parameters 






LVEF %, (n=212) 0.751
 ≥50 100(50) 10(53)
  31–49 72(36) 7 (37)
 ≤30 22(11) 1 (5)
LVLS, (n=198) −11.1±3.8 −10.9±3.6 0.783
MAPSE septal, cm 
(n=212)
0.70±0.27 0.67±0.31 0.691
MAPSE lateral, cm 
(n=212)
0.99±0.32 1.0±0.31 0.844
IVSDd, cm (n=202) 1.2±0.3 1.3±0.3 0.158
AVA, cm2 (n=215) 0.63±0.21 0.58±0.20 0.407
AVA index, cm2/m2 
(n=215)
0.34±0.11 0.34±0.11 0.802
AV gradient max, mm 
Hg (n=215)
84±24 77±20 0.189
AV gradient mean, 
mm Hg (n=215)
52±15 47±12 0.202
AV max velocity, m/s 
(n=216)
453±67 430±58 0.162
SV LVOT index, ml/m2 
(n=216)
37±11 35±12 0.559
LVOT diameter, cm 2.1±0.25 2.1±0.23 0.348
E/é (n=148) 19.2±8.1 18.1±9.7 0.644
E/A (n=147) 1.1±0.6 0.8±0.5 0.159
MV deceleration time, 
ms (n=215)
227±92 221±89 0.769
MV E, cm/s (n=215) 96±34 89±39 0.454
LA volume index, mL/
m2 (n=204)
53±20 53±22 0.995
MR moderate to 
severe (n=209)
38(20) 7 (37) 0.079
AR moderate to 
severe (n=213)
35(18) 3 (16) 0.777
Mitral stenosis 9 (5) 1 (5) 0.816
SPAP, mm Hg (n=215) 0.033
 >60 16(8) 5 (26)
  30–60 120(60) 10(53)
 <30 63(32) 4 (21)
TAPSE, cm (n=204) 1.6±0.5 1.7±0.5 0.405
TASV, cm/s (n=133) 9.5±3.2 10.9±3.3 0.140
FAC, % (n=197) 36±13 37±9 0.655
RVEDA, cm2 (n=197) 20±5 21±5 0.469
RVESA, cm2 (n=197) 13±5 13±3 0.872
TR moderate to 
severe (n=213)
40(21) 5 (26) 0.562







Values are mean±SD or n(%).
*Numbers in brackets indicate the number of cases where the 
measurement was available.
AR, aortic regurgitation; AV, aortic valve; AVA, aortic valve area; 
FAC, fractional area change; IVSDd, intraventricular septum 
diameter in diastole; LA, left atrium; LVLS, left ventricular 
longitudinal strain; LVEF, left ventricular ejection fraction; LVOT, 
left ventricular outflow tract; MAPSE, mitral annular plane systolic 
excursion; MR, mitral regurgitation; MV, mitral valve; RVEDA, right 
ventricular end-diastolic area; RVESA, right ventricular end-systolic 
area; RVLS, right ventricular longitudinal strain; SPAP, systolic 
pulmonary arterial pressure; SV, stroke vol; TAPSE, tricuspid 
annular peak systolic excursion; TASV, tricuspid annular systolic 
velocity; TR, tricuspid regurgitation.
Table 2 Continued
In a study based on 870 patients undergoing TAVI, 
Testa et al found that patients with TAPSE <10 mm had 
increased risk of mortality at 30 days13 in contrast to two 
other studies where TAPSE was not found to predict early 
mortality.14 15 Both RV dilation and reduced TAPSE have 
been linked to increased risk of long-term mortality.13 14 16 17 
Barvalia et al found TR to be an independent risk factor 
for early mortality after TAVI.18 To the best of our knowl-
edge, no other studies have identified any RV ventricular 
functional parameter as independent risk factor for early 
mortality besides elevated SPAP. The number of previous 
studies evaluating the effects of RV function on peripro-
cedural outcome is low and the RV functional parame-
ters included are often incomplete. Based on our results, 
the addition of speckle-tracking analysis did not yield any 
additional benefit in terms of evaluating the effect of RV 
nor LV function on early mortality.
Pulmonary hypertension
In all patients with pulmonary hypertension (PHT) in our 
cohort, we observed the two most common reasons for 
this condition; either COPD, heart failure or both. COPD 
has been identified as an important comorbid factor in 
patients undergoing TAVI with PHT.19 In contrast to 
large registry studies, we did not identify COPD as an 
independent predictor for early mortality.4–6 While mild 
PHT might be associated with reversible increased PAP 
in heart failure, markedly elevated PAP probably indi-
cates an irreversible condition in patients with heart 
failure that might not improve after TAVI. Irreversible 
PHT causes reduced cardio-circulatory reserve resulting 
in impaired ability to increase stroke volume and cardiac 
output. As a consequence, patients undergoing TAVI 
might have inadequate circulatory compensatory mech-
anism during and after the intervention in response to 
rapid load changes, anaesthesia and rapid pacing. Our 
finding of marked PHT as an independent risk factor for 
early mortality after TAVI is in accordance with data from 
several registry studies.3–6
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Table 3 Results of univariable and multivariable analysis for all-cause 30-day mortality
Variable 
Univariable Multivariable
P value HR 95% CI P value HR 95% CI
Body mass index, kg/m2 <0.000 0.78 0.68 to 0.90 <0.000 0.73 0.61 to 0.87
Heart failure 0.083 2.78 0.90 to 5.80 0.03 2.95 1.11 to 7.78
Access 0.004 0.017
  Transfemoral Ref  Ref
  Transaortic 0.905 0.88 0.10 to 7.51 0.614 0.57 0.06 to 5.14
  Transapical 0.011 4.98 1.78 to 13.99 0.015 3.8 1.29 to 11.16
SPAP, mm Hg 0.053 0.004
 <30 Ref  Ref
  30–60 0.737 1.22 0.38 to 3.89 0.688 1.28 0.39 to 4.14
 >60 0.038 4.03 1.08 to 14.99 0.004 7.77 1.90 to 31.28
Peripheral artery disease 0.002 5.16 1.86 to 14.34 0.002 5.95 1.97 to 17.99
MR moderate to severe 0.091 2.24 0.88 to 5.68 NS – –
COPD 0.065 1.40 1.01 to 7.79 NS – –
Previous cardiac surgery 0.101 0.43 0.15 to 1.18 NS – –
eGFR ml/min/1.73 m2 0.055 0.98 0.96 to 1.00 NS – –
Porcelain aorta 0.048 2.81 1.01 to 7.79 NS – –
COPD, chronic obstructive pulmonary disease; MR, mitral regurgitation;NS, non-significant; SPAP, systolic pulmonary arterial pressure; 
eGFR, estimated glomerular filtration rate.
Heart failure
Clinical signs of heart failure within 2 weeks prior to 
TAVI was an independent predictor of early mortality in 
our cohort. Opposed to physical and radiological signs 
of heart failure, the NYHA classification is based on limi-
tations on physical activity. The majority of our patients 
were classified as NYHA III-IV. The distinction between 
classes III and IV is subjective and might in addition to 
cardiac have its origin in respiratory, musculoskeletal and 
mental causes, or a combination of these factors. This 
might suggest that in this setting objective clinical signs of 
heart failure could be more helpful than only functional 
limitation when evaluating symptom severity. Further-
more, it may also indicate that optimisation of medical 
heart failure treatment prior to surgery might be a key 
factor to improve outcome.
Access and PAd
Central access, especially TA access, has emerged as a 
significant risk factor for early mortality compared with 
TF access.4 6 Compared with patients receiving TF-TAVI, 
these patients have a higher burden of comorbidities 
and higher preoperative risk based on preoperative 
surgical risk algorithms.20–22 Central access is also more 
invasive and requires surgical access via a limited thor-
acotomy or sternotomy, which might impair postoper-
ative respiratory effort secondary to pain. Our cohort 
had a low number of patients treated with TAo access, 
rendering to low power to assess if it is a significant risk 
factor. TF access depends on anatomical accessibility and 
adequate diameter of femoral and iliac vessels to facilitate 
instrumentation of introducer sheaths, but the presence 
of PAD does not necessarily result in a central access. If 
there are adequate diameter of access site vessels and 
satisfactory vascular anatomy proximally, TF access can 
be employed. Despite patients treated with central access 
having a higher burden of comorbidities, including PAD 
that might impact choice of access site, our data suggest 
that access and PAD are independent risk factors for 
early mortality. This might be due to factors related to 
the procedure itself, a consequence of patient selec-
tion or both. Whatever the reason, choice of access site 
is an important factor in risk evaluation when consid-
ering patients for TAVI as it seems to convey increased 
risk in itself. In addition to being a factor in the selec-
tion of access site, PAD reflects the patients’ vascular 
disease burden and has been shown to increase the risk 
of TF-TAVI vascular complications,23 which, in turn, has 
been associated with increased 30-day mortality.24 25 A 
meta-analysis by D'Ascenzo et al showed that the extent of 
coronary artery disease and the results of percutaneous 
coronary intervention (PCI), evaluated by Syntax Score 
and residual Syntax Score, respectively, were predictive 
of 1-year but not 30-day mortality.26 Despite not calcu-
lating Syntax Score in our cohort, we found no mortality 
difference between the groups with respect to previous 
myocardial infarction or PCI. In accordance with the 
aforementioned study, we found neither PCI nor previous 
myocardial infarction to be predictive of 30-day mortality. 
Although all patients in our cohort underwent TAVI 
under general anaesthesia, TF-TAVI is at present often 
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Valvular heart disease
Figure 2 Kaplan-Meier curves for each independent 
predictor stratified according to 30-day all-cause mortality. 
Heart failure defined as clinical signs of heart failure in the 
form of unusual dyspnoea on light exertion, orthopnoea, 
fluid retention, rales on auscultation, or pulmonary oedema 
on chest X-ray less than 2 weeks prior to TAVI. BMI, body 
mass index; eGFR, estimated glomerular filtration rate; PAD, 
peripheral artery disease; SPAP, systolic pulmonary arterial 
pressure; TAVI, transcatheter aortic valve implantation,
done in local anaesthesia and sedation, which has been 
shown to reduce 30-day mortality after TAVI.27 Although 
TA-TAVI being a valid option in clinical practice when 
TF access is not technically feasible, TF-TAVI should be 
considered the preferred modality.
BMI
The term ‘obesity paradox’ was first used to describe the 
increased early mortality after PCI in patients with low 
BMI28 and has also been observed in patients treated with 
TAVI.29–31 The VARC-2 consensus document states that 
frailty, where BMI<20 kg/m2 is a component, is among 
the risk factors not captured by traditional surgical risk 
scores.11 BMI might be a possible surrogate for frailty 
or cardiac cachexia in the TAVI population, but there 
are conflicting data whether low BMI confers risk in 
itself compared with the apparently protective effect of 
obesity.32 33 In our cohort, BMI was analysed as a contin-
uous variable and was still statistically significant even 
when patients with low BMI (<20 kg/m2) were excluded. 
Although we had few patients that were morbidly obese, 
our data suggest better survival with increasing BMI 
supporting the obesity paradox.
limitations
Compared with large registry studies, our study included 
patients from only two centres and was performed during 
an early stage after the implementation of TAVI as a treat-
ment option. This makes our findings less generalisable 
at present, and the results may be affected by center-and 
operator experience in addition to improvements in 
operative technique and equipment. Our inclusion 
criteria were rather strict and patients with lower preop-
erative risk are now offered TAVI, which may alter the risk 
considerably. Our univariable regression analysis resulted 
in several significant variables with the risk of low power 
in a relatively small cohort. This in general could be 
viewed as a limitation. However, since a forward multivar-
iable regression analysis was performed and all variables 
were highly significant, stricter inclusion criteria would 
not have changed the final model.
COnClusIOn
With the exception of elevated SPAP, our data suggest 
that clinical rather than echocardiographic parameters 
are more useful as predictors of 30-day mortality after 
TAVI. We identified SPAP >60 mm Hg, heart failure, TA 
access, PAD and BMI as independent predictors of 30-day 
mortality after TAVI. Our data suggest that these factors 
should be taken into consideration when evaluating high-
risk patients for TAVI.
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